US-based biotechnology company Moderna has taken a significant step in advancing mRNA (messenger RNA) research by introducing the mRNA Platform Incubator Network in Australia. This collaborative network brings together prominent Australian organizations with expertise in translational and pharmaceutical science, early-phase clinical trials, and regulatory science. The primary goal is to promote scientific excellence in clinical translation and further harness the therapeutic potential of the mRNA platform.
Promising Potential of mRNA
Moderna has officially partnered with the Australian Federal Government to establish an advanced domestic mRNA vaccine manufacturing facility in Melbourne, Victoria. This collaboration, following the initial announcement in December 2021, underscores Moderna’s commitment to supporting Australia’s mRNA research and global public health efforts. The facility will focus on producing mRNA vaccines for respiratory viruses like COVID-19, influenza, and RSV. Construction is set to begin by the end of 2022, with operational status expected by the end of 2024, subject to approvals. Moderna’s extensive mRNA pipeline includes 28 vaccine candidates targeting respiratory and latent viruses, addressing global health challenges.
Moderna‘s Regional Research Centre, inaugurated in August, will serve as the headquarters for this network of excellence. It includes prestigious institutions like Monash University, the Monash Institute of Pharmaceutical Sciences (MIPS), the Peter Doherty Institute, and The Peter MacCallum Cancer Centre. By combining the knowledge and expertise of these esteemed organizations, the Network aims to overcome specific clinical platform challenges and enhance mRNA therapeutics.
mRNA technology has been at the forefront of medical innovation, particularly in the development of COVID-19 vaccines like Spikevax. The Network’s mission involves developing scientific strategies to tackle challenges in the mRNA field. It also focuses on overseeing the practical implementation of these strategies, using non-clinical and computational quantitative pharmacology investigations, as well as translational clinical trials, led from Australia. This approach demonstrates the commitment to exploring mRNA’s therapeutic potential fully.
Elevating Australia as an mRNA Research Leader
Dr. Craig Rayner, Director of Moderna’s Regional Research Centre, emphasizes that the creation of the mRNA Platform Incubator Network underscores Australia’s emerging leadership in mRNA research. Professor Chris Porter, Director of the Monash Institute of Pharmaceutical Sciences, also highlights the importance of bringing together leaders in mRNA science from academia, industry, and clinical evaluation. This collaboration represents a significant step toward realizing the full potential of mRNA therapeutics. As mRNA technology continues to evolve and offer promising therapeutic options, this initiative is poised to contribute significantly to medical advancements and innovation in Australia.
Check out our mRNA service to expedite your vaccine research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
